Loading...
The continued use of anti–tumor necrosis factor (TNF) therapy during pregnancy for treatment of inflammatory bowel disease (IBD) is debated, as data on risks are conflicting. In a retrospective cohort study, researchers examined data from approximately 11,000 pregnancies in 8700 women with IBD receiving care under the French national health insurance system. They found that mothers exposed to an anti-TNF agent had a higher risk for infection during pregnancy compared with nonexposed women (adjusted odds ratio, 1.3). In an adjusted subgroup analysis, stopping anti-TNF therapy before the 24th week of amenorrhea was associated with doubled risk for disease relapse compared with continuing therapy beyond that point. No elevated risk for infecti…